S&P 500   3,980.06 (-2.66%)
DOW   31,915.89 (-2.26%)
QQQ   296.45 (-3.17%)
AAPL   143.69 (-3.72%)
MSFT   257.70 (-3.42%)
FB   196.78 (-2.88%)
GOOGL   2,263.40 (-2.84%)
AMZN   2,182.72 (-5.40%)
TSLA   737.29 (-3.19%)
NVDA   174.34 (-4.09%)
BABA   89.60 (-2.60%)
NIO   16.36 (-1.62%)
AMD   99.69 (-2.71%)
CGC   5.77 (-2.04%)
MU   72.36 (-2.85%)
T   20.36 (-1.02%)
GE   75.54 (-1.13%)
F   12.99 (-3.99%)
DIS   105.68 (-2.72%)
AMC   13.39 (+3.80%)
PFE   50.78 (-1.09%)
PYPL   78.41 (-1.68%)
NFLX   184.62 (-3.12%)
S&P 500   3,980.06 (-2.66%)
DOW   31,915.89 (-2.26%)
QQQ   296.45 (-3.17%)
AAPL   143.69 (-3.72%)
MSFT   257.70 (-3.42%)
FB   196.78 (-2.88%)
GOOGL   2,263.40 (-2.84%)
AMZN   2,182.72 (-5.40%)
TSLA   737.29 (-3.19%)
NVDA   174.34 (-4.09%)
BABA   89.60 (-2.60%)
NIO   16.36 (-1.62%)
AMD   99.69 (-2.71%)
CGC   5.77 (-2.04%)
MU   72.36 (-2.85%)
T   20.36 (-1.02%)
GE   75.54 (-1.13%)
F   12.99 (-3.99%)
DIS   105.68 (-2.72%)
AMC   13.39 (+3.80%)
PFE   50.78 (-1.09%)
PYPL   78.41 (-1.68%)
NFLX   184.62 (-3.12%)
S&P 500   3,980.06 (-2.66%)
DOW   31,915.89 (-2.26%)
QQQ   296.45 (-3.17%)
AAPL   143.69 (-3.72%)
MSFT   257.70 (-3.42%)
FB   196.78 (-2.88%)
GOOGL   2,263.40 (-2.84%)
AMZN   2,182.72 (-5.40%)
TSLA   737.29 (-3.19%)
NVDA   174.34 (-4.09%)
BABA   89.60 (-2.60%)
NIO   16.36 (-1.62%)
AMD   99.69 (-2.71%)
CGC   5.77 (-2.04%)
MU   72.36 (-2.85%)
T   20.36 (-1.02%)
GE   75.54 (-1.13%)
F   12.99 (-3.99%)
DIS   105.68 (-2.72%)
AMC   13.39 (+3.80%)
PFE   50.78 (-1.09%)
PYPL   78.41 (-1.68%)
NFLX   184.62 (-3.12%)
S&P 500   3,980.06 (-2.66%)
DOW   31,915.89 (-2.26%)
QQQ   296.45 (-3.17%)
AAPL   143.69 (-3.72%)
MSFT   257.70 (-3.42%)
FB   196.78 (-2.88%)
GOOGL   2,263.40 (-2.84%)
AMZN   2,182.72 (-5.40%)
TSLA   737.29 (-3.19%)
NVDA   174.34 (-4.09%)
BABA   89.60 (-2.60%)
NIO   16.36 (-1.62%)
AMD   99.69 (-2.71%)
CGC   5.77 (-2.04%)
MU   72.36 (-2.85%)
T   20.36 (-1.02%)
GE   75.54 (-1.13%)
F   12.99 (-3.99%)
DIS   105.68 (-2.72%)
AMC   13.39 (+3.80%)
PFE   50.78 (-1.09%)
PYPL   78.41 (-1.68%)
NFLX   184.62 (-3.12%)
NASDAQ:LABP

Landos Biopharma (LABP) Stock Forecast, Price & News

$0.79
+0.04 (+4.83%)
(As of 05/18/2022 11:10 AM ET)
Add
Compare
Today's Range
$0.77
$0.80
50-Day Range
$0.63
$1.83
52-Week Range
$0.61
$16.17
Volume
195 shs
Average Volume
130,701 shs
Market Capitalization
$31.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.49
30 days | 90 days | 365 days | Advanced Chart
Receive LABP News and Ratings via Email

Sign-up to receive the latest news and ratings for Landos Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Landos Biopharma logo

About Landos Biopharma

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA). Its preclinical candidates in development include LABP-66 is an oral and small molecule NOD-like pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA; LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; and LABP-111, an oral and small molecule LANCL2 pathway agonist for the treatment of nonalcoholic steatohepatitis and type 1 diabetes. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LABP
Fax
N/A
Employees
46
Year Founded
N/A

Sales & Book Value

Annual Sales
$18 million
Book Value
$1.90 per share

Profitability

Net Income
$-38.42 million
Pretax Margin
-241.49%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$31.65 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/12/2022
Today
5/18/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.03 out of 5 stars

Medical Sector

405th out of 1,426 stocks

Pharmaceutical Preparations Industry

169th out of 680 stocks

Analyst Opinion: 3.2Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -













Landos Biopharma (NASDAQ:LABP) Frequently Asked Questions

Is Landos Biopharma a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Landos Biopharma in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Landos Biopharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LABP, but not buy additional shares or sell existing shares.
View analyst ratings for Landos Biopharma
or view top-rated stocks.

When is Landos Biopharma's next earnings date?

Landos Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Landos Biopharma
.

How were Landos Biopharma's earnings last quarter?

Landos Biopharma, Inc. (NASDAQ:LABP) released its quarterly earnings data on Thursday, May, 12th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by $0.02.
View Landos Biopharma's earnings history
.

What price target have analysts set for LABP?

7 equities research analysts have issued 1-year price targets for Landos Biopharma's stock. Their forecasts range from $7.00 to $50.00. On average, they anticipate Landos Biopharma's stock price to reach $25.08 in the next year. This suggests a possible upside of 3,090.5% from the stock's current price.
View analysts' price targets for Landos Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Landos Biopharma's key executives?
Landos Biopharma's management team includes the following people:
  • Mr. Timothy M. Mayleben M.B.A., Pres, CEO & Director (Age 61, Pay $513.2k)
  • Dr. Raquel Hontecillas DVM, Ph.D., Chief Scientific Officer (Age 50, Pay $439.35k)
  • Dr. Josep Bassaganya-Riera DVM, Ph.D., Advisor (Age 47, Pay $1.79M) (LinkedIn Profile)
  • Ms. Patricia L. Bitar CPA, Interim Chief Financial Officer (Age 63)
When did Landos Biopharma IPO?

(LABP) raised $101 million in an initial public offering (IPO) on Thursday, February 4th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and SVB Leerink served as the underwriters for the IPO and Raymond James was co-manager.

What is Landos Biopharma's stock symbol?

Landos Biopharma trades on the NASDAQ under the ticker symbol "LABP."

Who are Landos Biopharma's major shareholders?

Landos Biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (1.29%), Renaissance Technologies LLC (0.85%) and Vanguard Group Inc. (0.39%). Company insiders that own Landos Biopharma stock include Josep Bassaganya-Riera, Konstantin Poukalov, Perceptive Advisors Llc and Rtw Investments, Lp.
View institutional ownership trends for Landos Biopharma
.

Which major investors are selling Landos Biopharma stock?

LABP stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc..
View insider buying and selling activity for Landos Biopharma
or view top insider-selling stocks.

Which major investors are buying Landos Biopharma stock?

LABP stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and BlackRock Inc.. Company insiders that have bought Landos Biopharma stock in the last two years include Konstantin Poukalov, Perceptive Advisors Llc, and Rtw Investments, Lp.
View insider buying and selling activity for Landos Biopharma
or or view top insider-buying stocks.

How do I buy shares of Landos Biopharma?

Shares of LABP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Landos Biopharma's stock price today?

One share of LABP stock can currently be purchased for approximately $0.79.

How much money does Landos Biopharma make?

Landos Biopharma has a market capitalization of $31.65 million and generates $18 million in revenue each year. The company earns $-38.42 million in net income (profit) each year or ($1.090010) on an earnings per share basis.

How many employees does Landos Biopharma have?

Landos Biopharma employs 46 workers across the globe.

What is Landos Biopharma's official website?

The official website for Landos Biopharma is landosbiopharma.com.

How can I contact Landos Biopharma?

Landos Biopharma's mailing address is 1800 KRAFT DRIVE SUITE 216, BLACKSBURG VA, 24060. The company can be reached via phone at 540-218-2232 or via email at [email protected].

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.